Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Xerava Generic Name & Formulations
Legal Class
Rx
General Description
Eravacycline 50mg; per vial; lyophilized pwd for IV infusion after reconstitution and dilution; preservative-free.
Pharmacological Class
Tetracycline antibiotic.
How Supplied
Single-dose vials—1, 12
Manufacturer
Generic Availability
NO
Xerava Indications
Indications
Susceptible complicated intra-abdominal infections (cIAI) in patients ≥18yrs of age.
Limitations of Use
Not for the treatment of complicated urinary tract infections (cUTI).
Xerava Dosage and Administration
Adult
Calculate dose based on actual body weight. Give by IV infusion over 60mins. ≥18yrs: 1mg/kg every 12hrs for 4–14 days. Severe hepatic impairment (Child Pugh C): 1mg/kg every 12hrs on Day 1, then 1mg/kg every 24hrs starting on Day 2 for a total duration of 4–14 days. Concomitant strong CYP3A inducers: 1.5mg/kg every 12hrs for a total duration of 4–14 days.
Children
<8yrs: not recommended.
Xerava Contraindications
Not Applicable
Xerava Boxed Warnings
Not Applicable
Xerava Warnings/Precautions
Warnings/Precautions
Discontinue if allergic reaction or superinfection occurs. Evaluate if diarrhea occurs; discontinue if C. difficile-associated diarrhea is suspected or confirmed. Pregnancy (during 2nd & 3rd trimester): may cause permanent discoloration of the teeth or reversible inhibition of bone growth. Nursing mothers: not recommended (during and for 4 days after the last dose).
Xerava Pharmacokinetics
See Literature
Xerava Interactions
Interactions
May be antagonized by strong CYP3A inducers; increase dose (see Adults). May need to reduce concomitant anticoagulant dose.
Xerava Adverse Reactions
Adverse Reactions
Infusion site reactions, nausea, vomiting, diarrhea, hypotension, wound dehiscence; hypersensitivity reactions, tooth discoloration, enamel hypoplasia, inhibition of bone growth (up to 8yrs of age), C.difficile-associated diarrhea, photosensitivity, pseudotumor cerebri, increased BUN, azotemia, acidosis, hyperphosphatemia, pancreatitis, abnormal LFTs.
Xerava Clinical Trials
See Literature
Xerava Note
Not Applicable
Xerava Patient Counseling
See Literature
Images
